Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

430
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
430

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Aberrant retinal structure and vasculature in mouse models of dominant retinopathies caused by CRX homeodomain mutations.

Scientific reports·2026
Same author

Clinical Outcomes and Predictors of Retinal Breaks in Patients With Vitreous Hemorrhage Secondary to a Posterior Vitreous Detachment.

Journal of vitreoretinal diseases·2026
Same author

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same author

RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

Investigative ophthalmology & visual science·2026
Same author

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Expert opinion on biological therapy·2026
Same author

Lipemia Retinalis as a Masquerader of Multiple Myeloma.

Retina (Philadelphia, Pa.)·2026

相关实验视频

Updated: Jun 25, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.7K

针对增殖性玻璃红蛋白病变的干预措施

Wilson X Wang1, Maggie Xing1, Rajendra S Apte1

  • 1John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri.

JAMA ophthalmology
|May 23, 2024
PubMed
概括
此摘要是机器生成的。

药理干预措施在预防增殖性玻璃红蛋白病变方面表现出有限的有效性. 目前可用的选择缺乏高质量的证据来有效预防这种疾病.

更多相关视频

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

7.8K
Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
11:06

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Published on: November 11, 2022

2.7K

相关实验视频

Last Updated: Jun 25, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.7K
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

7.8K
Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
11:06

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Published on: November 11, 2022

2.7K

科学领域:

  • 眼科医生 眼科 眼科
  • 视网膜疾病 视网膜疾病
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 增殖性视网膜病变 (PVP) 是视网膜脱落手术后视力损失的重要原因.
  • 目前的管理策略通常涉及手术干预,但预防仍然是一个挑战.

研究的目的:

  • 评估药理干预措施在预防增殖性玻璃红蛋白病变方面的有效性.
  • 评估支持PVP预防现有药理选择的证据质量.

主要方法:

  • 临床试验和观察性研究的系统审查.
  • 对调查PVP预防药理学剂的研究进行分析.

主要成果:

  • 有限的高质量证据支持目前药理干预措施在预防PVP方面的有效性.
  • 需要进一步的研究来确定有效的药理疗法.

结论:

  • 现有的药理选择没有在预防增殖性玻璃红蛋白病变方面表现出强大的疗效.
  • 基于证据的药理学策略的开发对于改善患者的治疗结果至关重要.